2367 — Giant Biogene Holding Co Income Statement
0.000.00%
Last trade - 00:00
- HK$50.00bn
- HK$45.93bn
- CNY3.52bn
- 87
- 15
- 97
- 79
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 957 | 1,190 | 1,552 | 2,364 | 3,524 |
Cost of Revenue | |||||
Gross Profit | 797 | 1,007 | 1,354 | 1,995 | 2,947 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 280 | 217 | 580 | 1,187 | 1,779 |
Operating Profit | 677 | 973 | 973 | 1,178 | 1,745 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 677 | 973 | 973 | 1,178 | 1,745 |
Provision for Income Taxes | |||||
Net Income After Taxes | 575 | 826 | 828 | 1,002 | 1,448 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 552 | 826 | 828 | 1,002 | 1,452 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 552 | 826 | 828 | 1,002 | 1,452 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.566 | 0.831 | 0.841 | 1.47 | 1.48 |
Dividends per Share | |||||
Special Dividends per Share |